The Securities and Exchange Commission filings that Spark released Monday confirm what became apparent when the FTC announced it was subjecting the Roche buyout...
Dive Insight:
Biogen took the most severe blow in its history last month, losing more than $20 billion in market capitalization on the announcement that the...
Deloitte's annual report on R&D productivity, while limited in scope, is an indicator of the challenges faced by large pharmaceutical firms in bringing new molecules...
Bluebird declined to release the Zynteglo price when the agent received European Commission conditional approval last week. The price announcement Friday coincided with a...
The plaques are considered hallmarks of Alzheimer's disease, formed in the brain from sticky clusters of a misfolded protein fragment called beta-amyloid.
For the past...
TherapeuticsMD decided against diluting its shareholders again in order to get Bijuva (estradiol and progesterone) and Annovera (segesterone acetate and ethinyl estradiol) off the...
Four months after Morphic reached an R&D deal with AbbVie, the Waltham, Massachusetts-based biotech has found another drugmaking giant to partner with.
Morphic and AbbVie...
The administration faces increasing pressure to release a concrete healthcare plan as Democratic presidential candidates are eager to keep the national conversation focused...
Novo is best known for its insulin products like Levemir (insulin detemir) and Tresiba (insulin degludec), as well as other diabetes treatments like...
